Dai Yaoyao, Gao Sicheng, Liu Xing, Gao Qin, Zhang Lan, Fan Xingliang, Zhu Junfeng
Department of Hepatology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200070, China.
Department of Central Laboratory Medicine, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
Evid Based Complement Alternat Med. 2018 Dec 17;2018:9196409. doi: 10.1155/2018/9196409. eCollection 2018.
We aim to conduct a meta-analysis of studies on the effect of Aidi injection combined with TACE in the treatment of hepatocellular carcinoma (HCC). China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database (CBM), Chinese Science and Technology Periodical Database (VIP), Allied and Complementary Medicine Database (AMED), EMBASE, Web of Science, PubMed, and Cochrane Library databases to October 1, 2017, were searched to collect the studies. The data analysis was performed using RevMan 5.3 software. Totally 20 clinical trials with 774 (the experimental group: 447 cases; the control group: 327 cases) HCC patients were finally included in this meta-analysis. Meta-analysis results showed that Aidi injection combined with TACE can, to some extent, enhance the clinical effect and improve the overall survival. Meanwhile, it can increase HCC patients' quality of life. Additionally, Aidi injection plus TACE can reduce adverse events including leukopenia, gastrointestinal reaction, and liver damage in HCC patients (all P < 0.05). Therefore, Aidi injection plus TACE may significantly enhance the clinical effect, suggesting that the combination of TCM and western medicine is promising. The exact outcome needs rigorously designed performances, multicenter, and large randomized controlled trials.
我们旨在对艾迪注射液联合肝动脉化疗栓塞术(TACE)治疗肝细胞癌(HCC)的研究进行荟萃分析。检索了中国知网(CNKI)、万方数据库、中国生物医学文献数据库(CBM)、维普中文科技期刊数据库(VIP)、补充与替代医学数据库(AMED)、荷兰医学文摘数据库(EMBASE)、科学引文索引(Web of Science)、美国国立医学图书馆生物医学文献数据库(PubMed)以及考克兰图书馆数据库,截至2017年10月1日,以收集相关研究。使用RevMan 5.3软件进行数据分析。本荟萃分析最终纳入了20项临床试验,共774例HCC患者(试验组:447例;对照组:327例)。荟萃分析结果显示,艾迪注射液联合TACE在一定程度上可提高临床疗效,改善总生存期。同时,可提高HCC患者的生活质量。此外,艾迪注射液联合TACE可减少HCC患者的不良事件,包括白细胞减少、胃肠道反应和肝损伤(均P<0.05)。因此,艾迪注射液联合TACE可能显著提高临床疗效,提示中西医结合具有广阔前景。确切结果需要经过严格设计的多中心、大样本随机对照试验来验证。